Integration of Omics in Mental Disorders: Understanding Molecular Connectivity from Prediction to Prevention

A variety of environmental factors, including stressors, contribute to mental disease. Unmet medical outcomes and monitoring platforms in the field of mental illnesses currently necessitate the implementation of sensitivity associated with key biomarkers in the detection, evaluation, and validation processes. The use of omics in mental disorders and in a health care assessment platform, which is based on macromolecule-dependent data analysis such as bioinformatics, has the potential to increase the identification of risk genes and treatment options by validating the functional efficacy of drugs or recovery status of brain function using behavioral assessment and metabolomics, which includes a neuro-pharmacogenomics study. This concept may appear futuristic, but it is great. If multiple databases around the world continue to grow, increasing the likelihood of identifying a strand, health professionals such as clinicians and lab scientists will be able to predict the likelihood of a disease outbreak, drug addiction, and synaptic malfunction, as well as the likelihood that a treatment will work. Although practical adoption may take some time, the therapeutic alternative, which comprises biological and synthetic products, will be well worth the wait. In this paper, we give a short review of mental disease with unknown etiology by visualizing risk genes and functional vulnerability in molecular diagnostic developments utilizing the Omics platform. The future perspective of using the Omics platform shed light on the venue in biomarker exploration, innovation, and evaluation of assessment procedures in a clinical setting for the treatment of mental health disorders looks promising.